Nektar Therapeutics | NKTR - Loan Capital


Nektar Therapeutics reported $60.27M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 1.48B 7.23M Jun/2026
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
Amgen USD 51.86B 27M Jun/2026
Baxter International USD 8.62B 6M Jun/2026
BioCryst Pharmaceuticals USD 395.4M 203K Jun/2026
Biogen USD 7.29B 1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Cara Therapeutics USD 0 0 Mar/2025
Cipla INR 3.82B 840.2M Mar/2026
Dr.Reddys Laboratories INR 12.2B 595M Mar/2026
Eisai JPY 184.6B 49.83B Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Grifols EUR 9.95B 722.93M Dec/2025
Halozyme Therapeutics USD 1.94B 1.79M Jun/2026
Incyte USD 28.42M 994K Jun/2026
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
MacroGenics USD 68.71M 1.29M Mar/2026
Merck USD 51.08B 4.41B Jun/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.49B 42M Jun/2026
Pfizer USD 60.5B 70M Jun/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Takeda JPY 4.42T 50.32B Jun/2026
Teva Pharmaceutical Industries USD 12.09B 1.92B Jun/2026
Xencor USD 77.54M 4.59M Jun/2026